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cardiac failure (of nonspecific origin) is similarly high, ifToday patients with chronic renal failure die no longer
not higher (Table 1). It is therefore unlikely that coro-from the direct sequelae of uremia, except in under-
nary heart disease (CHD) fully explains the excess risk.developed countries. Nevertheless, the life expectancy
Apart from atherosclerosis of the epicardial conduitof dialysed patients continues to be severely reduced,
arteries and poorly defined cardiomyopathy, however,mainly as a consequence of fatal cardiovascular events
features related to uremia per se (or to hemodialysis(CV). The excess cardiovascular risk is demonstrable
per se) must play an important role, as suggested by theeven in early stages of renal failure and remains elevated
comparison between transplanted patients and patientsto some extent even after renal transplantation. Re-
on the waiting list [7, 8]: Rapid improvement of survivalversing the excessive cardiovascular risk is currently the
after transplantation is seen particularly in high risk pa-greatest challenge to clinical nephrology.
tients, i.e., the diabetic or elderly patient.
EPIDEMIOLOGY
ARE THERE DIFFERENCES INA high rate of CV death in dialysis patients had been
CARDIOVASCULAR RISK FACTORSdocumented early on in the 1970s [1], and this has re-
BETWEEN PATIENTS WITH ANDmained unchanged according to more recent European
WITHOUT RENAL DISEASE?[2] and US-American [3] registry reports. The late A.
Both autopsy [9] and angiography studies [10] docu-Raine had documented that the risk of fatal ischemic
ment a high prevalence of coronary lesions in patientsheart disease relative to the background population was
with renal disease. The morphology of coronary plaqueshigher by a factor of approximately 15–20 [2], and this
in the uremic compared to non-uremic patients is charac-has more recently been confirmed by Foley [4]. He
terized by a high prevalence of aggressive calcificationshowed that, depending on age, survival in the dialysed
[11] which is in line with the results of electron-beampatient is lower by a factor of 20 (at age 20–30 years)
CT [12, 13]. In view of the aggressive biology of coronaryand by approximately 2 (at age above 80 years). It is of
plaques in renal failure, this finding is somewhat unex-note that the life expectancy of 50 year old HD patients
pected, because calcification tends to stabilize plaques.is comparable to that of patients with some metastasising
However, it has also been postulated that rupture maycancers [5].
occur at the boundary between calcified and non-calcifiedWhat is the specific cause of death in HD patients?
tissue. The most dreaded culprit is the soft plaque proneEver since the seminal article by Lindner [6], it has been
to rupture. The tendency of plaques to calcify is notedknown that myocardial infarction is more frequent com-
early on, because a high prevalence of calcified carotidpared with the background population. Nevertheless, sev-
plaques has been noted even in patients with incipienteral studies show that the contribution of sudden death and
renal failure [14].
It is obvious that apart from accelerated CHD, other
cardiac abnormalities must be considered and some of1 ISN Fellowship.
2 Present address: Department of Internal Medicine, University of Hei- these are summarized in Table 2.
delberg, Bergheimer Str. 56 a D-69115, Heidelberg, Germany. There are good arguments that cardiac ischemia toler-
ance is reduced in patients with renal failure because ofKey words: uremia, hypertension, anemia, sympathetic activity, dyslip-
idemia. left ventricular hypertrophy (LVH) [15] and particularly
microvascular disease [16]. In the evolution of LVH, con- 2002 by the International Society of Nephrology
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Table 1. Most frequent causes of death in diabetic and non-diabetic
hemodialyzed patients
Diabetic Non-diabetic
Cardiac arrest 59.4 42.4
Septicaemia 30.5 19.9
Myocardial infarction 26.7 16.7
Cardiac arrythmia 16.0 11.7
Stroke 16.8 11.3
Other 46.5 44.7
(Rates are per 1.000 patient-years at risk in the years 1996–1998) (after [3]).
Fig. 1. Comparison of insulin-dependent glucose uptake in the isolated
prefused heart of rats with uremia, P  0.01. (after reference 23).
Table 2. Abnormalities potentially increasing cardiovascular
risk in renal failure
Table 3. Classical and non-classical cardiovascularCoronary heart disease
risk factors in renal failureLeft ventricular hypertrophy (concentric, excentric)
Cardiac microvascular disease
Classical risk factors Non-classical risk factorsImpaired elasticity of central arteries
Sympathetic overactivity and denervation suprasensitivity Hypertension Anemia
Abnormalities of myocardial metabolism Hypervolemia Hyperphosphatemia?
Dyslipidemia Hyperparathyroidism?
Sympathetic overactivity Microinflammation?
Hyperhomocysteinemia?
centric LVH is initially observed; it tends to be later super-
seded by excentric LVH, i.e., LV dilatation, further raising
wall stress. The coronary reserve, i.e., the increase in coro- in mortality when diabetic patients had undergone myo-
nary blood flow in response to higher demand, is reduced. cardial infarction [25]. In uremia, a further metabolic
This finding is has functional as well as structural causes abnormality of the heart is the instability of energy-rich
[16]. Nitric oxide (NO) is an important mediator for vascu- nucleotides under conditions of ischemia [26].
lar dilatation. Its availability is presumably decreased be- It emerges from the above that there are multiple ab-
cause the concentration of asymmetric dimethyl-l-argi- normalities of cardiac structure and function in uremia.
nine (ADMA) is increased, even in early renal failure, Consequently, it would be naive to assume that there is
[17] and because NO is scavenged by reactive oxygen one single intervention, a “golden bullet” so to speak
species [18]. In addition, thickening of the arteriolar wall that would abrogate all cardiovascular risks.
is seen as in syndrome X, i.e., in patients with angina
pectoris and patent coronary arteries [19]. Arteriolar
AT WHAT POINT IN RENAL FAILURE DOEShypertrophy/hyperplasia [20] presumably limits the va-
THE CARDIOVASCULAR RISK INCREASE?sodilatory capacity. Finally, a mismatch between cardio-
myocytes and capillaries increases the distance that oxy- Table 3 lists some established and some hypothetical
CV risk factors in renal failure.gen has to diffuse from the center of the capillaries to
the center of cardiomyocytes, thus rendering the LV sus- It is remarkable that classic risk factors are demonstra-
ble in the very early stages of renal disease. Even whenceptible to hypoxia. Under-capillarization of the myocar-
dium points to some disturbance in angiogenesis [21, 22]. inulin clearance is still within the normal range, we could
demonstrate a rise in blood pressure, lipoprotein a [Lp(a)]Finally, adaptation to ischemia/hypoxia may be limited
by metabolic abnormalities. In the isolated Langen- [28] as well as ADMA, an inhibitor of NO synthase [29].
A normal whole kidney inulin clearance obviously doesdorff’s preparation. Our group had shown [23] that insu-
lin-mediated glucose uptake is impaired in the heart of not exclude reduction of the number of nephrons (and
of functional parenchyma), because it may be compen-the uremic rat (Fig. 1), and this is associated with dimin-
ished expression of GLUT-4 in the plasma membrane sated by single nephron hyperfiltration.
It is currently hotly debated whether apart from the(unpublished data). This abnormality should interfere
with the capacity of the LV to generate ATP through classic risk factors defined in non-renal populations such
as the Framingham study (Table 3), non-classic risk fac-glycolysis during hypoxia when mitochrondrial oxidation
as the source of ATP generation has become insufficient tors operate in renal failure as well, e.g. anemia, hyper-
phosphatemia, and hyperparathyroidism. Block et al [30][24]. Such a defect may be of relevance because the
DIGAMI (Diabetes Mellitus, insulin Glucose Ingusion showed that increased pre-dialytic serum phosphate con-
centrations increase the risk of cardiovascular death inin Acute Myocardial Infarction) study showed that infu-
sion of glucose and insulin causes a spectacular reduction dialysed patients, although this finding has not been con-
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firmed by all subsequent investigators. It is currently un- Blood pressure/hypervolemia
clear whether hyperphosphatemia is a surrogate marker Observational studies strongly indicate that mean arte-
of under-dialysis or whether it is responsible for increas- rial pressure [45] and, possibly even more, pulse pressure
ing the CV risk, either indirectly, e.g., via increasing PTH, [46] predict cardiac death. Impressive reversal of eccen-
or directly, e.g., via calcification of coronary arteries [31]. tric LVH by control of hypervolemia despite no admini-
PTH excess definitely increases the risk of arterial abnor- nistration of antihypertensive agents was reported by
malities and interstitial fibrosis in the heart of uremic O¨zkaya [47].
rats [29, 32], providing a further rationale to keep PTH
Blockade of the renin angiotensin systemconcentrations in the normal range.
Epidemiologic studies in non-renal patients [33] show The HOPE trial showed that administration of rami-
that increased concentrations of C-reactive protein (CRP), pril reduced the event rate in non-renal patients at high
i.e., a marker of the acute phase response (“microin- CV risk [48], particularly in diabetics in whom the CV
flammation”) are a predictor of CV risk. The same is risk is higher by a factor of 3. It may be argued that the
found in dialyzed patients [34, 35]. Increased concentra- same consideration should apply to renal patients, where
tions of markers of the acute phase response, i.e., in- the CV risk is increased by a factor of 4–20 [2, 38]. A
terleukin-6 and CRP, are found even in early stages of rationale for the use of ACE inhibitors may be provided
renal failure. Thus renal failure per se elicits an acute by the observation that both the systemic and the local
phase response, although undoubtedly this is further ag- renin angiotensin system in the vessel wall are activated
gravated by dialysis. One interesting possibility has to in renal failure [49]. In one study, blood pressure-inde-
be considered [36]. In patients with congestive heart pendent reduction of LVH was noted on administration
failure hypervolemia and hypothetical edema of the in- of ACE inhibitors [50].
testinal mucosa are thought to increase the permeability
Dyslipidemiato bacterial lipopolysaccharides, thus provoking an acute
phase response that is reversible after administration of There is a paradoxical inverse relationship between
serum cholesterol and CV risk [51], presumably becausediuretics [37]. If the same mechanism can be documented
low total cholesterol is a surrogate marker for malnutri-in patients with renal failure, a strong argument would
tion. This finding certainly does not indicate that highbe provided for intense efforts to reduce hypervolemia.
cholesterol per se is beneficial. More sophisticated analy-All the above established or hypothetical risk factors
sis showed that there is a U-shaped relationship, andmay explain why in renal patients cardiovascular mortal-
both very high and very low cholesterol concentrationsity is increased by a factor of 2–4 even before end-stage
are associated with increased risk [52]. Analysis of lipidrenal failure [38]. It is therefore also not surprising that
fractions may not be sufficiently sensitive, however. Apo-actuarial survival in patients with confirmed CHD is simi-
lipoprotein concentrations are more informative and arelarly poor in patients pre-dialysis and in patients on dial-
clearly related to the presence of vascular pathology [53].ysis [39]. When patients start dialysis, stenosis docu-
The 4D Study [44] is designed to investigate whethermented by coronary angiography have been reported in
lipid lowering reduces CV mortality in dialysed type 2more than 50% of patients [40]. Although some selection
diabetics, but it is worth remembering that statines maybias cannot be excluded, LVH is even found in up to
be beneficial independent of their effects on plasma lipid70% [41].
concentrations via reduction of intracellular isoprenylThese observations give us a clear message: In order to
compounds [54].reduce the high mortality in dialysed patients, prevention
must start very early in the course of renal disease.
Sympathetic overactivity
Sudden death is the most common mode of death in
IS PREVENTION POSSIBLE? dialysed patients. In this context, it is important that both
We live in the age of evidence-based medicine. Unfor- in uremic animals [55] and in patients with renal disease
tunately, apart from very small series [42], no controlled [56] increased sympathetic activity is demonstrable. This
information is available. Uncontrolled observational can be shown even when GFR is still normal. It has been
studies suggest benefit from intervention, however [43]. documented that intrarenal chemo- and baroreceptors
It is hoped that at least with respect to lipid lowering by are activated by renal damage, raising catecholamine
statines, an ongoing large controlled trial will provide turnover in the hypothalamus and increasing efferent
evidence for benefit (or lack thereof) [44]. Even in the sympathetic nerve traffic. As shown in Figure 2, in the
absence of controlled evidence, much can be deduced renal ablation model a reduced renal norepinephrine
by sound clinical reasoning and application of patho- content is found (as an index of rarefaction of sympa-
thetic nerve supply) and at the same time an increasedphysiological a priori considerations.
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mine receptors occurs causing denervation suprasensitiv-
ity, so that under these circumstances the heart is particu-
larly sensitive to increased sympathetic activity (though
this has not been directly demonstrated in renal failure).
This consideration led to the postulate that beta-blockers
should be used more widely in uremic patients [58]. In
a controlled study, Cice examined dialysis patients with
congestive heart failure and showed that survival and
ejection fraction were considerably improved by the ad-
ministration of the beta-blocker carvedilol [59]. The
safety of administration of beta-blockers had been docu-
mented by Agarwal [60]. Alternatively central sympa-
thetic blockade may be beneficial for the heart as shown
at least in animal experiments [61]. It deserves men-
tioning that pharmacologic blockade of the sympathetic
activity also interferes with progression in experimental
models [57] and in humans [62].
Diabetes control
Diabetes is a co-morbid condition in up to 50% of
patients entering renal replacement programs. Optimal
management of diabetes is therefore an important issue.
A study from Taiwan showed that poor glycemic control
prior to the onset of dialysis was a strong predictor of
reduced survival on dialysis [63]. Zager et al showed
that in diabetic patients on hemodialysis with HbA1c
concentrations above 7.5% the mortality was higher by
65% (abstract; J Am Soc Nephrol 11:124A, 2000).
Anemia
It would be intuitively plausible that reversal of ane-
mia improves ischemia tolerance of the LV and reduces
the development of LVH. Indeed, a relationship be-
tween hematocrit and survival as well as CV events has
been documented in dialyzed patients [65], but the re-
sults of an interventional trial on normalization of the
hematocrit failed to provide evidence of a benefit [66].
In dialyzed patients with established LVH or LV dilata-
tion, it is impossible to reverse these cardiac abnormali-
ties, at least in the short term, whereas in dialyzed [67]
and presumably also in pre-dialysis patients [68] preven-
tion of these cardiac abnormalities appears to be feasible.
CARDIOVASCULAR PREVENTION TODAY?Fig. 2. Reduced renal cortical norepinephrine content as an index of
sympathetic nerve density (A) in the present increased stimulation- In view of the fascinating spectrum of possibilities ofinduced release of 3-H-Norepinephrine from prelabeled tissue and
prevention, one would anticipate that intensive wide-nerve fibers as an index of greater activity of the renal sympathetic
nerve system (B). Symbols are: control (open box); SNX (shaded box). spread efforts be made to treat renal patients at an early
(after [57]).
stage to prevent hypertension, hypervolemia, dyslipid-
emia, anemia, hyperphosphatemia, etc. The reality is so-
bering, however. The major factor is late referral [69].
NE turnover (as an index of increased sympathetic activ- Late referral is associated with higher morbidity, e.g.,
ity) [57]. Why is this relevant? In the partially denervated hospitalization, and, at least in the first year of dialysis,
higher mortality. In the high risk population of diabeticheart, it has been shown that upregulation of catechola-
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